Immutep Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
3.93
Dividend yield
-
Beta
1.69
Market cap
$566.69M
Enterprise value
$459.08M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.immutep.com |
| Mailing address | Australia Square Level 32 264 George Street Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 8315 7003 / 61 2 8569 1880 |
Dividends
More: Immutep Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Immutep paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IMM dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Immutep.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Marc Voigt | CEO, MD, CFO, Chief Business Officer & Executive Director | 52 | |
| Ms. Deanne Miller LLB | COO, General Counsel & Joint Company Secretary | 48 | |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer & Executive Director | 70 | |
| Mr. Christian Mueller BBA, MSc. | Chief Development Officer | ||
| Dr. Stephan Winckels M.D., Ph.D. | Chief Medical Officer | ||
| Ms. Indira Naidu | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-2035.47%
Return on assets
-22.66%
Return on equity
-36.88%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Immutep is 566.69M and its enterprise value is 459.08M. The enterprise value to revenue ratio of IMM is 91.02. The enterprise value to EBITDA ratio of IMM is -7.30.
The IMM's stocks Beta value is 1.69 making it 69% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Immutep (IMM)
Immutep (ASX:IMM) Frequently Asked Questions
1. What is Immutep's Stock Symbol?
Immutep trades on ASX under the ticker symbol "IMM".
2. What is Immutep's stock price today?
One share of IMM stock can currently be purchased for approximately $0.385.
3. How can I contact Immutep?
Immutep's mailing address is Australia Square Level 32 264 George Street Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8315 7003.
4. What is Immutep's official website?
The official website of Immutep is https://www.immutep.com.